BioAtla, Inc. (BCAB): Price and Financial Metrics
GET POWR RATINGS... FREE!
BCAB POWR Grades
- BCAB scores best on the Value dimension, with a Value rank ahead of 39.57% of US stocks.
- BCAB's strongest trending metric is Quality; it's been moving down over the last 179 days.
- BCAB's current lowest rank is in the Momentum metric (where it is better than 4.64% of US stocks).
BCAB Stock Summary
- BCAB's went public 1.28 years ago, making it older than merely 1.42% of listed US stocks we're tracking.
- BCAB's price/sales ratio is 701.64; that's higher than the P/S ratio of 99.34% of US stocks.
- With a year-over-year growth in debt of 687.54%, BioAtla Inc's debt growth rate surpasses 97.87% of about US stocks.
- Stocks that are quantitatively similar to BCAB, based on their financial statements, market capitalization, and price volatility, are CLNN, SAGE, BLUE, CGEM, and FREQ.
- Visit BCAB's SEC page to see the company's official filings. To visit the company's web site, go to www.bioatla.com.
BCAB Valuation Summary
- BCAB's price/sales ratio is 3238; this is 85110.53% higher than that of the median Healthcare stock.
- Over the past 37 weeks, BCAB's price/sales ratio has gone up 3053.1.
- Over the past 37 weeks, BCAB's price/sales ratio has gone up 3053.1.
Below are key valuation metrics over time for BCAB.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| BCAB | 2021-08-31 | 3238.0 | 7.8 | -38.7 | -34.3 |
| BCAB | 2021-08-30 | 3189.3 | 7.7 | -38.2 | -33.7 |
| BCAB | 2021-08-27 | 3220.0 | 7.8 | -38.5 | -34.1 |
| BCAB | 2021-08-26 | 3034.0 | 7.3 | -36.3 | -31.8 |
| BCAB | 2021-08-25 | 3215.2 | 7.7 | -38.5 | -34.0 |
| BCAB | 2021-08-24 | 3309.8 | 8.0 | -39.6 | -35.2 |
BCAB Price Target
For more insight on analysts targets of BCAB, see our BCAB price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $76.25 | Average Broker Recommendation | 1.3 (Strong Buy) |
BCAB Stock Price Chart Interactive Chart >
BCAB Price/Volume Stats
| Current price | $2.44 | 52-week high | $51.83 |
| Prev. close | $2.31 | 52-week low | $2.01 |
| Day low | $2.22 | Volume | 220,100 |
| Day high | $2.47 | Avg. volume | 692,486 |
| 50-day MA | $3.71 | Dividend yield | N/A |
| 200-day MA | $17.80 | Market Cap | 91.29M |
BioAtla, Inc. (BCAB) Company Bio
BioAtla LLC develops conditionally active biologic antibody therapeutics. The firm's technologies include conditionally active biologics, comprehensive integrated antibody optimization, CPE and CPS, gigamab, and versitop. The company was founded by Jay M. Short and Carolyn Anderson in March 2007 and is headquartered in San Diego, CA.
Latest BCAB News From Around the Web
Below are the latest news stories about BioAtla Inc that investors may wish to consider to help them evaluate BCAB as an investment opportunity.
Monashee Investment Management LLC Buys Vanguard Total Stock Market ETF, Hyperfine Inc, Agree ...Investment company Monashee Investment Management LLC (Current Portfolio) buys Vanguard Total Stock Market ETF, Hyperfine Inc, Agree Realty Corp, Pardes Biosciences Inc, DocGo Inc, sells Maravai LifeSciences Holdings Inc, SomaLogic Inc, MoneyLion Inc, RBC Bearings Inc, BioAtla Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Monashee Investment Management LLC. |
Jefferies Thinks BioAtla’s Stock is Going to RecoverJefferies analyst Kelly Shi maintained a Buy rating on BioAtla (BCAB – Research Report) yesterday and set a price target of $68.00. The company's shares closed last Friday at $12.63, close to its 52-week low of $11.96. According to TipRanks.com, Shi is ranked 0 out of 5 stars with an average return of -19.9% and a 17.9% success rate. Shi covers the Healthcare sector, focusing on stocks such as Bicycle Therapeutics, Heron Therapeutics, and Legend Biotech. Currently, the analyst consensus on BioAtla is a Strong Buy with an average price target of $64.67, which is a 412.4% upside from current levels. |
Analysts’ Top Healthcare Picks: Exact Sciences (EXAS), BioAtla (BCAB)There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Exact Sciences (EXAS – Research Report), BioAtla (BCAB – Research Report) and Stoke Therapeutics (STOK – Research Report) with bullish sentiments. Exact Sciences (EXAS) In a report released yesterday, Mark Massaro from BTIG reiterated a Buy rating on Exact Sciences, with a price target of $120.00. The company's shares closed last Tuesday at $76.19, close to its 52-week low of $73.41. According to TipRanks. |
The Daily Biotech Pulse: Illunina Announces Multiple Partnerships, Immunome Slides On Regulatory Setback For COVID Antibody Drug, Preannouncements Pour InHere''s a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus BioAtla, Bristol-Myers Squibb Announce Collaboration To Evaluate ADC-Opdivo Combo In Solid… |
BioAtla collaborates with Bristol Myers Squibb for lead assetsBioAtla (BCAB) has added ~3.1% in the post-market after the company announced a clinical collaboration with Bristol Myers Squibb (BMY) to study its lead candidates BA3011 and BA3021 |
BCAB Price Returns
| 1-mo | -34.41% |
| 3-mo | -63.25% |
| 6-mo | -89.76% |
| 1-year | -94.33% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -87.57% |
| 2021 | -42.28% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...